.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Merck
Express Scripts
Mallinckrodt
Chinese Patent Office
Queensland Health
Moodys
US Army
Accenture
Baxter

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,696,206

« Back to Dashboard

Which drugs does patent 7,696,206 protect, and when does it expire?


Patent 7,696,206 protects STAXYN and LEVITRA and is included in two NDAs. There have been zero Paragraph IV challenges on Staxyn and Levitra

This patent has eighty-four patent family members in forty-six countries.

Summary for Patent: 7,696,206

Title:2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
Abstract:The application claims a compound of the formula ##STR00001## or a salt, a hydrate, or a hydrate of a salt thereof. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of erectile dysfunction.
Inventor(s): Niewohner; Ulrich (Wermelskirchen, DE), Niewohner, legal representative; Maria (Wermelskirchen, DE), Es-Sayed; Mazen (Langenfeld, DE), Haning; Helmut (Wuppertal, DE), Schenke; Thomas (Bergisch Gladbach, DE), Schlemmer; Karl-Heinz (Wuppertal, DE), Keldenich; Jorg (Wuppertal, DE), Bischoff; Erwin (Wuppertal, DE), Perzborn; Elisabeth (Wuppertal, DE), Dembowsky; Klaus (Boston, MA), Serno; Peter (Bergisch Gladbach, DE), Nowakowski; Marc (Wuppertal, DE)
Assignee: Bayer Schering Pharma Aktiengesellschaft (Berlin, DE)
Application Number:12/569,720
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Bayer HlthcareSTAXYNvardenafil hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL200179-001Jun 17, 2010RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF ERECTILE DYSFUNCTION
Bayer HlthcareLEVITRAvardenafil hydrochlorideTABLET;ORAL021400-003Aug 19, 2003ABRXYesNo► Subscribe► Subscribe► SubscribeYYERECTILE DYSFUNCTION
Bayer HlthcareLEVITRAvardenafil hydrochlorideTABLET;ORAL021400-001Aug 19, 2003ABRXYesNo► Subscribe► Subscribe► SubscribeYYERECTILE DYSFUNCTION
Bayer HlthcareLEVITRAvardenafil hydrochlorideTABLET;ORAL021400-002Aug 19, 2003ABRXYesNo► Subscribe► Subscribe► SubscribeYYERECTILE DYSFUNCTION
Bayer HlthcareLEVITRAvardenafil hydrochlorideTABLET;ORAL021400-004Aug 19, 2003ABRXYesYes► Subscribe► Subscribe► SubscribeYYERECTILE DYSFUNCTION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,696,206

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany197 50 085Nov 12, 1997
Germany198 12 462Mar 23, 1998
Germany198 40 289Sep 04, 1998

Non-Orange Book Patents for Patent: 7,696,206

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,362,178 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors► Subscribe
7,704,9992-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors► Subscribe
7,122,5402-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors► Subscribe
7,314,8712-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors, for treatment of hypertension► Subscribe
6,890,922 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors► Subscribe
6,566,360 2-phenyl substituted imidatriazinones as phosphodiesterase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,696,206

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China1508137► Subscribe
China100430396► Subscribe
Colombia4980861► Subscribe
Cyprus1112949► Subscribe
Czech Republic20001759► Subscribe
Czech Republic301911► Subscribe
Germany19750085► Subscribe
Germany19812462► Subscribe
Germany19840289► Subscribe
Germany19881732► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
US Army
QuintilesIMS
Colorcon
Medtronic
Queensland Health
Healthtrust
Johnson and Johnson
Argus Health
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot